Actions of peroxisome proliferator-activated receptors-gamma agonists explaining a possible blood pressure-lowering effect.

[1]  Erland Erdmann,et al.  Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial , 2005, The Lancet.

[2]  C. Nicol,et al.  PPARγ in endothelial cells influences high fat diet-induced hypertension , 2005 .

[3]  H. Koide,et al.  Effect of pioglitazone on carotid intima-media thickness and arterial stiffness in type 2 diabetic nephropathy patients. , 2004, Metabolism: clinical and experimental.

[4]  K. Kohara,et al.  Improvement of insulin resistance by troglitazone ameliorates cardiac sympathetic nervous dysfunction in patients with essential hypertension , 2004, Journal of hypertension.

[5]  C. Yosefy,et al.  Rosiglitazone Improves, While Glibenclamide Worsens Blood Pressure Control in Treated Hypertensive Diabetic and Dyslipidemic Subjects via Modulation of Insulin Resistance and Sympathetic Activity , 2004, Journal of cardiovascular pharmacology.

[6]  Y. Tsai,et al.  Hypertension and abnormal fat distribution but not insulin resistance in mice with P465L PPARgamma. , 2004, The Journal of clinical investigation.

[7]  E. Ferrannini,et al.  Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes. , 2004, Diabetes care.

[8]  P. Maheux,et al.  Rosiglitazone increases extravasation of macromolecules and endothelial nitric oxide synthase in skeletal muscles of the fructose-fed rat model. , 2004, Biochemical pharmacology.

[9]  D. Dazzi,et al.  Pioglitazone reduces blood pressure in non-dipping diabetic patients. , 2004, Minerva endocrinologica.

[10]  S. Mathur,et al.  PPAR&ggr; Agonist Rosiglitazone Improves Vascular Function and Lowers Blood Pressure in Hypertensive Transgenic Mice , 2004, Hypertension.

[11]  M. Hanefeld,et al.  In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. , 2004, Diabetes care.

[12]  M. Lokhandwala,et al.  Rosiglitazone Restores G-Protein Coupling, Recruitment, and Function of Renal Dopamine D1A Receptor in Obese Zucker Rats , 2004, Hypertension.

[13]  A. Dobrian,et al.  Pioglitazone Prevents Hypertension and Reduces Oxidative Stress in Diet-Induced Obesity , 2004, Hypertension.

[14]  S. Vasdev,et al.  Dietary vitamin E supplementation lowers blood pressure in spontaneously hypertensive rats , 2002, Molecular and Cellular Biochemistry.

[15]  B. Kingwell,et al.  Rosiglitazone lowers blood pressure and increases arterial compliance in postmenopausal women with type 2 diabetes. , 2003, Diabetes care.

[16]  A. Vinik,et al.  Rosiglitazone treatment increases nitric oxide production in human peripheral skin: a controlled clinical trial in patients with type 2 diabetes mellitus. , 2003, Journal of diabetes and its complications.

[17]  R. Zimlichman,,et al.  Treatment with rosiglitazone reduces hyperinsulinemia and improves arterial elasticity in patients with type 2 diabetes mellitus. , 2003, American journal of hypertension.

[18]  A. Nadeau,et al.  Effect of troglitazone on vascular and glucose metabolic actions of insulin in high-sucrose-fed rats. , 2003, Metabolism: clinical and experimental.

[19]  D. Schuster,et al.  Long-term cardiovascular effects of insulin sensitizer troglitazone on non-diabetic individuals with insulin resistance: double blind, prospective randomized study. , 2003, Journal of cardiology.

[20]  S. Lewington.  Prospective studies collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies (vol 360, pg 1903, 2002) , 2003 .

[21]  A. Baron,et al.  Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome. , 2003, The Journal of clinical endocrinology and metabolism.

[22]  E. Schiffrin,et al.  Effect of Peroxisome Proliferator–Activated Receptor-&agr; and -&ggr; Activators on Vascular Remodeling in Endothelin-Dependent Hypertension , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[23]  T. Okumura,et al.  Troglitazone reduces activity of the Na+/H+ exchanger in fructose-fed borderline hypertensive rats. , 2003, Hypertension research : official journal of the Japanese Society of Hypertension.

[24]  R. Collins,et al.  Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies , 2002, The Lancet.

[25]  A. Banday,et al.  Rosiglitazone Treatment Restores Renal Dopamine Receptor Function in Obese Zucker Rats , 2002, HYPERTENSION.

[26]  K. Usadel,et al.  Effects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. , 2002, The Journal of clinical endocrinology and metabolism.

[27]  N. Fukuda,et al.  Troglitazone inhibits growth and improves insulin signaling by suppression of angiotensin II action in vascular smooth muscle cells from spontaneously hypertensive rats. , 2002, Atherosclerosis.

[28]  E. Schiffrin,et al.  Structure, Endothelial Function, Cell Growth, and Inflammation in Blood Vessels of Angiotensin II–Infused Rats: Role of Peroxisome Proliferator–Activated Receptor-&ggr; , 2002, Circulation.

[29]  M. Trovati,et al.  Influence of insulin and of insulin resistance on platelet and vascular smooth muscle cell function. , 2002, Journal of diabetes and its complications.

[30]  N. Sarraf-zadegan,et al.  Vitamin E can reduce blood pressure in mild hypertensives. , 2002, International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition.

[31]  R. Nagai,et al.  Troglitazone improves endothelial function and augments renal klotho mRNA expression in Otsuka Long-Evans Tokushima Fatty (OLETF) rats with multiple atherogenic risk factors. , 2001, Hypertension research : official journal of the Japanese Society of Hypertension.

[32]  C. Marcantoni,et al.  Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats. , 2001, Kidney international.

[33]  P. Little,et al.  Troglitazone, but not rosiglitazone, inhibits Na/H exchange activity and proliferation of macrovascular endothelial cells. , 2001, Journal of diabetes and its complications.

[34]  L. Landsberg.  Insulin-mediated sympathetic stimulation: role in the pathogenesis of obesity-related hypertension (or, how insulin affects blood pressure, and why) , 2001, Journal of hypertension.

[35]  W. Hsueh,et al.  Expression and Function of Peroxisome Proliferator–Activated Receptor-γ in Mesangial Cells , 2001 .

[36]  W. Hsueh,et al.  Control of vascular cell proliferation and migration by PPAR-gamma: a new approach to the macrovascular complications of diabetes. , 2001, Diabetes care.

[37]  H. Lebovitz,et al.  Insulin resistance and its treatment by thiazolidinediones. , 2001, Recent progress in hormone research.

[38]  Lebovitz He,et al.  Insulin resistance and its treatment by thiazolidinediones. , 2001 .

[39]  Millard H. Lambert,et al.  PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ∞ AND METABOLIC DISEASE , 2001 .

[40]  W. Hsueh,et al.  Expression and function of peroxisome proliferator-activated receptor-gamma in mesangial cells. , 2001, Hypertension.

[41]  K. Takeda,et al.  Peroxisome Proliferator-Activated Receptor γ Activators Downregulate Angiotensin II Type 1 Receptor in Vascular Smooth Muscle Cells , 2000 .

[42]  K. Shimada,et al.  Troglitazone improves endothelial dysfunction in patients with insulin resistance. , 2000, Journal of atherosclerosis and thrombosis.

[43]  W. Hsueh,et al.  Peroxisome Proliferator-activated Receptor γ Ligands Inhibit Retinoblastoma Phosphorylation and G1 → S Transition in Vascular Smooth Muscle Cells* , 2000, The Journal of Biological Chemistry.

[44]  M. Roncaglioni,et al.  Effects of low-dose aspirin on clinic and ambulatory blood pressure in treated hypertensive patients , 2000 .

[45]  M. Roncaglioni,et al.  Effects of vitamin E on clinic and ambulatory blood pressure in treated hypertensive patients , 2000 .

[46]  E. Fleck,et al.  Troglitazone inhibits mitogenic signaling by insulin in vascular smooth muscle cells. , 2000, Journal of cardiovascular pharmacology.

[47]  W. Hsueh,et al.  Expression and Function of PPARγ in Rat and Human Vascular Smooth Muscle Cells , 2000 .

[48]  A. Takeshita,et al.  Peroxisome proliferator-activated receptor gamma activators downregulate angiotensin II type 1 receptor in vascular smooth muscle cells. , 2000, Circulation.

[49]  M. Roncaglioni,et al.  Effects of vitamin E on clinic and ambulatory blood pressure in treated hypertensive patients. Collaborative Group of the Primary Prevention Project (PPP)--Hypertension study. , 2000, American journal of hypertension.

[50]  T. Yoshimoto,et al.  Vasculo-protective effects of insulin sensitizing agent pioglitazone in neointimal thickening and hypertensive vascular hypertrophy. , 1999, Atherosclerosis.

[51]  G. Williams,et al.  The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats. , 1999, Diabetes.

[52]  Michael F. Wilson,et al.  Vasodilatory effects of troglitazone improve blood pressure at rest and during mental stress in type 2 diabetes mellitus. , 1999, Hypertension.

[53]  T. Saruta,et al.  Altered pressure-natriuresis in obese Zucker rats. , 1999, Hypertension.

[54]  P. Aaronson,et al.  Differential effects of insulin-sensitizers troglitazone and rosiglitazone on ion currents in rat vascular myocytes. , 1999, European journal of pharmacology.

[55]  A. Sidawy,et al.  Insulin action enhancement normalizes brachial artery vasoactivity in patients with peripheral vascular disease and occult diabetes. , 1998, Journal of vascular surgery.

[56]  M. Fujishima,et al.  Mechanisms of vasorelaxation induced by troglitazone, a novel antidiabetic drug, in the porcine coronary artery. , 1998, Circulation.

[57]  G. Ailhaud,et al.  Insulin down-regulates angiotensinogen gene expression and angiotensinogen secretion in cultured adipose cells. , 1998, Biochemical and biophysical research communications.

[58]  M. Fujishima,et al.  Troglitazone, an insulin sensitizer, increases forearm blood flow in humans. , 1998, American journal of hypertension.

[59]  P. Zimmet,et al.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation , 1998, Diabetic medicine : a journal of the British Diabetic Association.

[60]  E. Arikawa,et al.  Direct Vasodepressor Effects of Pioglitazone in Spontaneously Hypertensive Rats , 1998, Pharmacology.

[61]  J. Sowers,et al.  Disparate effects of antidiabetic drugs on arterial contraction. , 1997, Metabolism: clinical and experimental.

[62]  T. Kotchen,et al.  Increasing insulin sensitivity lowers blood pressure in the fructose-fed rat. , 1997, American journal of hypertension.

[63]  H. Itoh,et al.  Reduction of insulin resistance attenuates the development of hypertension in sucrose-fed SHR. , 1997, Life sciences.

[64]  T. Yoshimoto,et al.  Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats. , 1997, The American journal of physiology.

[65]  M. Barbagallo,et al.  Altered Ionic Effects of Insulin in Hypertension : Role of Basal Ion Levels in Determining Cellular Responsiveness , 1997 .

[66]  M. Ghazzi,et al.  Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group. , 1997 .

[67]  Julio E. Pérez,et al.  Cardiac and Glycemic Benefits of Troglitazone Treatment in NIDDM , 1997, Diabetes.

[68]  D. Faxon,et al.  Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. , 1996, The Journal of clinical investigation.

[69]  T. Buchanan,et al.  Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect. , 1995, The Journal of clinical investigation.

[70]  B. Ludvik,et al.  Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. , 1994, The New England journal of medicine.

[71]  J. Sowers,et al.  Effects of pioglitazone on calcium channels in vascular smooth muscle. , 1994, Hypertension.

[72]  T. Kotchen,et al.  Pioglitazone attenuates hypertension and inhibits growth of renal arteriolar smooth muscle in rats. , 1993, The American journal of physiology.

[73]  E. Ferrannini,et al.  Relationship between insulin release, antinatriuresis and hypokalaemia after glucose ingestion in normal and hypertensive man. , 1993, Clinical science.

[74]  M. Wada,et al.  Antihypertensive effects of CS-045 treatment in obese Zucker rats. , 1993, Metabolism: clinical and experimental.

[75]  M. Laakso,et al.  Impaired Insulin-Mediated Skeletal Muscle Blood Flow in Patients With NIDDM , 1992, Diabetes.

[76]  M. Saad,et al.  Insulin resistance in essential hypertension. , 1990, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[77]  G. Reaven.  Role of Insulin Resistance in Human Disease , 1988, Diabetes.